Genzyme Bets Big on Biosurgery
Executive Summary
Genzyme Corp is merging two of its subsidiaries, Genzyme Tissue Repair and Genzyme Surgical with a third company, Biomatrix Inc. in a bold bet on the promise of biosurgery--the combination of biomaterials and gene and cellular therapies with more traditional surgical instruments. Clinically, biosurgery will hopefully improve patient outcomes; commercially, it will differentiate surgical instrument makers whose products seem increasingly alike.You may also be interested in...
Medtech Companies Need To Do Better At Patient Engagement, Expert Says
A top clinical research expert says the medical device industry is lagging behind the pharmaceutical industry when it comes to engaging patients. While industry groups are pushing for more patient preference be factored in in regulatory decisions, John Lewis of patient advocacy group Heart Valve Voice says medtech companies themselves are not investing enough in this area.
European Debut For CMR Surgical’s Versius Surgical Robot In Two UK NHS Hospitals
CMR Surgical’s Versius robotic system is now live in the UK NHS, the company announced 20 February.
Teva Emerges From Restructuring Ready To Grow
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Need a specific report? 1000+ reports available
Buy Reports